Dr. Ferrer BioPharma
Dr. Ferrer BioPharma is a private Florida-based pharmaceutical company developing intranasal and oronasal drug delivery therapies and medical devices using its proprietary GentleMist technology, targeting consumers with coughs, colds, flu, and allergies across the U.S., Panama, and Dominican Republic.
- Company typePrivate
- Founded2020
- HeadquartersHallandale, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Dr. Ferrer BioPharma does
Dr. Ferrer BioPharma (legal name: Ferrer Medical Innovations, LLC D/B/A Dr. Ferrer BioPharma) is a private pharmaceutical and medical device company founded in 2020 and headquartered at 701 N Federal Hwy Suite 501, Hallandale Beach, Florida. The company specializes in intranasal and oronasal drug delivery therapies for the treatment of coughs, colds, flu, and allergies, serving both consumer and healthcare-provider end markets. Its core platform is the proprietary GentleMist Technology, a nasal spray delivery system that uses optimized fluid dynamics and aerosol science to deposit metered doses directly to the nasal mucosa with low irritation, designed to address patient non-compliance caused by the burning and discomfort associated with conventional nasal sprays.
The company operates a two-product-line model. The Finished Formulations line includes ClorNasal (intranasal anti-allergy/rhinitis spray), ClorNovir (antiviral nasal spray for influenza and COVID-19), ClorRelief (adult throat spray), ClorRelief Kids (pediatric throat spray for ages 4-12), and the in-development TriMist (nasal congestion spray). The Medical Devices line includes the GentleMist Nozzle, OralMist Pro atomizer, Ferrer EndoScope, ISO 8836:2019-compliant Flexible Closed Suction Catheter, IntegraView point-of-care ultrasound (POCUS) device, and PrecisaDose precision oral dosing pump. ClorRelief products are sold direct-to-consumer through Amazon with Prime eligibility; medical devices and bulk pharmaceutical products are sold through a B2B inquiry-based channel; and ClorNasal is distributed via pharmacy partnerships in Panama and Dominican Republic.
Revenue mechanics are a mix of one-time consumer purchases (Amazon), reseller/pharmacy distribution (Latin America), and enterprise B2B device sales. The company has won the Pharmapack 2024 Patient-Centric Design Award for GentleMist and was a finalist at the CPHI Pharma Awards 2022 in Finished Formulation. No funding rounds or revenue figures are publicly disclosed, and no management team profiles are available in the source data.
Dr. Ferrer BioPharma firmographics
Firmographics- Name
- Dr. Ferrer BioPharma
- Legal name
- Ferrer Medical Innovations, LLC D/B/A Dr. Ferrer BioPharma
- Website
- https://drferrerbiopharma.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Dr. Ferrer BioPharma is a private Florida-based pharmaceutical company developing intranasal and oronasal drug delivery therapies and medical devices using its proprietary GentleMist technology, targeting consumers with coughs, colds, flu, and allergies across the U.S., Panama, and Dominican Republic.
- Ownership category
- akta.pro rank
Dr. Ferrer BioPharma industry classification
Industry- Product category
- Intranasal Drug Delivery and Respiratory Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Respiratory & Allergy Pharmaceuticals (HLAIAAAH)
- akta.pro secondary industries
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
Keywords
Where Dr. Ferrer BioPharma is headquartered
LocationHeadquarters
- HQ city
- Hallandale
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Dr. Ferrer BioPharma business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Finished Formulation Products: Sale of pharmaceutical finished formulations including ClorNasal (nasal spray for allergies/rhinitis), ClorNovir (antiviral nasal spray), ClorRelief (throat spray), and ClorRelief Kids (pediatric throat spray). Products sold directly to consumers via Amazon marketplace and through pharmacies in Panama and Dominican Republic
- Medical Devices: Sale of proprietary medical devices including GentleMist technology nozzle, Flexible Closed Suction Catheter (ISO 8836:2019 compliant), IntegraView POCUS ultrasound device, and OralMist Pro atomizer
- Pipeline Products: Upcoming product launches including TriMist intranasal spray for nasal congestion and PrecisaDose precision oral dosing pump for tramadol drops
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | ClorRelief - Adult Throat Spray |
| Unit Pricing | Pay-as-you-go | ClorRelief Kids - Pediatric Throat Spray (Ages 4-12) |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Dr. Ferrer BioPharma product offering
Product offeringCore offering
Dr. Ferrer BioPharma develops, manufactures, and commercializes intranasal and oronasal pharmaceutical formulations and proprietary drug-delivery medical devices for the treatment of coughs, colds, flu, allergies, and respiratory conditions. Its finished formulations (ClorNasal, ClorNovir, ClorRelief, ClorRelief Kids) and medical devices (GentleMist Nozzle, OralMist Pro, IntegraView POCUS, Flexible Closed Suction Catheter, Ferrer EndoScope, PrecisaDose) are powered by the company's proprietary GentleMist Technology platform, which uses optimized fluid dynamics and aerosol science for precise, low-irritation metered dosing.
Product overview
Dr. Ferrer BioPharma offers a portfolio of oronasal therapies organized into two main categories: Finished Formulations (pharmaceutical products) and Medical Devices. The Finished Formulations include ClorNasal (nasal spray for allergies/rhinitis), ClorNovir (antiviral nasal spray), ClorRelief (throat spray for adults), and ClorRelief Kids (pediatric throat spray), all powered by the proprietary GentleMist Technology for comfortable delivery. The Medical Devices portfolio includes the GentleMist Nozzle system, OralMist Pro atomizer, Ferrer EndoScope, Flexible Closed Suction Catheter, IntegraView POCUS portable ultrasound, and PrecisaDose precision dosing pump. A pipeline product, TriMist, is in development for nasal congestion relief.
Differentiator
Problem solved
Functional benefit
Brands
- GentleMist Technology: Proprietary nasal drug delivery technology using optimized fluid dynamics and aerosol science for precise, comfortable dosing to nasal mucosa
- OralMist Pro
- IntegraView POCUS
- PrecisaDose
- ClorNasal
- ClorNovir
- ClorRelief
- ClorRelief Kids
- Ferrer EndoScope
- Flexible Closed Suction Catheter
- TriMist
Products and services
- ClorNasal Intranasal anti-allergy and anti-rhinitis treatment spray using cutting-edge nanoparticle technology to provide fast and effective relief from allergy and rhinitis symptoms. Equipped with the proprietary GentleMist nozzle for no-burn, no-pain delivery. Targeted at adult consumers and pharmacy distribution.
- ClorNovir
Quantifiable outcome
- 99.7% reduction in SARS-CoV-2 viral load in vitro after 25 minutes with chlorpheniramine maleate nasal spray
- +2 more outcomes
Companies that use Dr. Ferrer BioPharma
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
Dr. Ferrer BioPharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Dr. Ferrer BioPharma partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- CPHI (Co-organized with Pharmapack)coreActive participation in CPHI events including CPHI Paris 2025 - one of the most influential global gatherings for pharmaceutical innovation. Participation allows connection with industry leaders, showcasing commitment to advanced healthcare solutions, and exploring new collaboration opportunities.
- PharmapackcoreWon Pharmapack Awards 2024 Patient-Centric Design Award for GentleMist Technology. Pharmapack is a major pharmaceutical packaging and drug delivery event that recognizes innovative solutions in the industry.
- Panama Pharmacy NetworkcoreClorNasal officially launched in Panama through events showcasing product history and key benefits. Active distribution through pharmacy partners throughout Panama, recognizing the city's climate makes protection against environmental changes crucial.
- Dominican Republic Pharmacy NetworkcoreClorNasal continues to grow in Dominican Republic through strong partnerships and active community presence. Includes pharmacy visits, key events, and press briefings demonstrating local market impact.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
Dr. Ferrer BioPharma competitors and assessment
Company assessmentBroad incumbents
- Perrigo Company: Perrigo is a large OTC consumer healthcare company with deep respiratory and allergy categories (store-brand equivalents of Claritin, Flonase, etc.), competing head-on with Dr. Ferrer BioPharma's OTC throat and nasal sprays on Amazon and in pharmacy channels.
- Church & Dwight: Church & Dwight owns consumer healthcare brands in cough, cold, and allergy (e.g., Zicam) and competes in the same OTC respiratory aisle where Dr. Ferrer BioPharma's ClorRelief and ClorNovir products compete.
- Prestige Consumer Healthcare: Prestige Consumer Healthcare is an OTC consumer health company with respiratory and throat care brands (e.g., Chloraseptic, Little Remedies) competing directly in the throat spray and pediatric cough/cold categories where Dr. Ferrer BioPharma operates.
- Bausch Health: Bausch Health operates a large consumer healthcare portfolio including Allegra, Nasacort, and other respiratory/allergy brands, making it a relevant incumbent comparable for Dr. Ferrer BioPharma's intranasal allergy and cold/flu products.
- Becton, Dickinson and Company (BD): BD is a large medical device company with a respiratory care portfolio including closed suction catheters and airway management devices, overlapping directly with Dr. Ferrer BioPharma's ISO 8836:2019 compliant Flexible Closed Suction Catheter.
- Teva Pharmaceutical Industries: Teva is a major generic and specialty pharma with significant nasal spray and respiratory franchises (e.g., fluticasone, ProAir), serving the same allergies, cold, and flu categories as Dr. Ferrer BioPharma.
Direct peers
- OptiNose: OptiNose is a specialty pharma built around a proprietary intranasal drug delivery platform targeting allergic rhinitis and chronic nasal conditions, making it the closest direct comparable to Dr. Ferrer BioPharma's GentleMist technology and intranasal allergy franchise.
- Xlear: Xlear is a smaller nasal-spray-focused company selling over-the-counter nasal care products for allergies, congestion, and sinus health, directly overlapping with Dr. Ferrer BioPharma's ClorNasal and ClorRelief SKUs in the OTC intranasal category.
Emerging players
- Emergent BioSolutions: Emergent BioSolutions developed Narcan (naloxone) as an intranasal spray drug-device combination product for emergency use, comparable to Dr. Ferrer BioPharma's ClorNovir antiviral intranasal concept in combining a novel API with intranasal delivery.
Others
- Aptar Pharma: Aptar Pharma is a leading drug delivery device manufacturer, including nasal spray pumps and valves used by many branded respiratory products. It is comparable as both a potential supplier/competitor on the device side of Dr. Ferrer BioPharma's GentleMist nozzle business.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Dr. Ferrer BioPharma social profiles
Digital presenceDr. Ferrer BioPharma compliance and trust
Trust signalCompliance1 record
Dr. Ferrer BioPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dr. Ferrer BioPharma leadership team
Management profileNumber of profiles
Dr. Ferrer BioPharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dr. Ferrer BioPharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dr. Ferrer BioPharma
What does Dr. Ferrer BioPharma do?
Dr. Ferrer BioPharma develops, manufactures, and commercializes intranasal and oronasal pharmaceutical formulations and proprietary drug-delivery medical devices for the treatment of coughs, colds, flu, allergies, and respiratory conditions. Its finished formulations (ClorNasal, ClorNovir, ClorRelief, ClorRelief Kids) and medical devices (GentleMist Nozzle, OralMist Pro, IntegraView POCUS, Flexible Closed Suction Catheter, Ferrer EndoScope, PrecisaDose) are powered by the company's proprietary GentleMist Technology platform, which uses optimized fluid dynamics and aerosol science for precise, low-irritation metered dosing.
Is Dr. Ferrer BioPharma a public or private company?
Dr. Ferrer BioPharma is a private company. It is classified as unknown and is currently operating.
When was Dr. Ferrer BioPharma founded?
Dr. Ferrer BioPharma was founded in 2020. It employs 11 to 50 people.
Where is Dr. Ferrer BioPharma based?
Dr. Ferrer BioPharma is headquartered in Hallandale, United States, in the North America region.
How does Dr. Ferrer BioPharma make money?
Three revenue lines are on record. Finished Formulation Products are the primary driver. The others are medical Devices and pipeline Products.
Who are Dr. Ferrer BioPharma's main competitors?
Broad incumbents on record are Perrigo Company, Church & Dwight, Prestige Consumer Healthcare, Bausch Health, Becton, Dickinson and Company (BD) and Teva Pharmaceutical Industries. Direct peers are OptiNose and Xlear. Emergent BioSolutions is listed as an emerging player. Aptar Pharma is listed as an others.
Does Dr. Ferrer BioPharma have an API?
No public API is recorded for Dr. Ferrer BioPharma.
What industry is Dr. Ferrer BioPharma in?
Dr. Ferrer BioPharma's product category is Intranasal Drug Delivery and Respiratory Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals, with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.